Novel Frontline Therapy Strategies in Acute Myeloid Leukemia
Naval Davar
To update molecular biology of myelodyspastic syndrome (MDS) and Acute myeloblastic leukaemia (AML) as well as to discuss use of novel targeted agents in the treatment of both MDS and AML
Enrolled 3

About Novel Frontline Therapy Strategies in Acute Myeloid Leukemia

Myelodysplastic syndrome (MDS) is the commonest of hematological malignancy. However, hematologists find it difficult to diagnose it with accuracy as there is no single test which is diagnostic. Clinical picture, morphology, cytogenetics and molecular tests compliment each other. Clinical severity is variable with some having survival in decades while others succumb within 1-2 years. Next-generation sequencing (NGS) based molecular testing has boosted the diagnostic skills and also added to targeted therapies using novel agents.
In the field of acute myeloblastic leukaemia (AML), there was no break through in the treatment for almost 2 decades. During 2018-19, almost half a dozen molecules have received US FDA approval and hence greatly enhanced survival of these patients. Today's presentation will review these molecules.
This course is relevant for Clinical Hematologists, Hematopathologists, Medical Oncologists and Fellows doing superspecialization in these fields 


  • Chapters
    1. Chapter 01
    2. Chapter 02
    3. Chapter 03
    4. Chapter 04
    5. Chapter 05
    6. Chapter 06
    7. Chapter 07

About Naval Davar

Associate Professor & Director, Leukaemia Research Alliance Program at MD Anderson Cancer Center, Houston, Texas, USA.


Novel Frontline Therapy Strategies in Acute Myeloid Leukemia
By Naval Davar
Rs. 0
Grand Total
Rs. 0